New Treatment Addressing the Pathogenesis of Psoriasis.
New Treatment Addressing the Pathogenesis of Psoriasis.
复制标题
新的治疗方法解决牛皮癣的发病机制。
DOI：
10.3390/ijms21207488
复制
发表时间：
2020-10-11
影响因子：
5.6
通讯作者：
Mabuchi T
中科院分区：
文献类型：
--
作者：
Tokuyama M;Mabuchi T
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.
登录
查看更多内容
影响因子：
6.4
作者：
Collin M;McGovern N;Haniffa M
通讯作者：
Haniffa M
影响因子：
11.5
作者：
Banerjee S;Biehl A;Gadina M;Hasni S;Schwartz DM
通讯作者：
Schwartz DM
影响因子：
6.5
作者：
Auriemma, Matteo;Brzoska, Thomas;Loser, Karin
通讯作者：
Loser, Karin
影响因子：
7.3
作者：
Bolli, Martin H.;Abele, Stefan;Weller, Thomas
通讯作者：
Weller, Thomas
影响因子：
4.5
作者：
Borodzicz S;Rudnicka L;Mirowska-Guzel D;Cudnoch-Jedrzejewska A
通讯作者：
Cudnoch-Jedrzejewska A